Clinical trial
Human Papilloma Virus (HPV) Vaccine Trial in Young Adolescent Women With…
NCT00316706 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00316706 |
|---|---|
| Title | Human Papilloma Virus (HPV) Vaccine Trial in Young Adolescent Women With GlaxoSmithKline Biologicals' (GSK Bio) HPV-16/18 Vaccine |
| Official title | A Long-term, Open Follow-up of the Immunogenicity and Safety of GSK Biologicals' HPV Vaccine (580299) in Healthy Female Subjects Vaccinated in Study HPV-013 |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Cervical Intraepithelial Neoplasia, Papillomavirus Infection |
| Intervention type | Biological |
| Interventions | GSK Biologicals' HPV-16/18 Vaccine (Cervarix™), Havrix™ |
| Enrollment | 1,245 |
| Start date | Oct 1, 2005 |
| Primary completion | Jan 1, 2009 |
| Completion | Jan 1, 2009 |
| First posted | Apr 21, 2006 |
| Last update posted | Sep 18, 2012 |
| Countries | Colombia, Germany, Honduras, Panama, Taiwan |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: